BioSpace News Archive

Histogen Inc. announced that Histogen’s financial results for the second quarter ended June 30, 2022 will be released after the close of market on Thursday, August 11, 2022.

Forecast to 2030,’ thoroughly examines the Prostate Biopsy Devices industry to provide essential data & information for the targeted readers.

GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved Benlysta (belimumab) for the treatment of children aged 5 to 17 with active lupus nephritis (LN) who are receiving standard therapy.

Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company, reiterated today what it had previously disclosed in 2021, that certain government agencies had requested information from the Company.

If you want to track a person’s activities for a day, you could call them up every ten minutes and ask what they’re doing.

CARF International announced that Pacific Quest has been accredited for a period of three years for its adolescent and young adult programs.

Align Technology, Inc., a leading global medical device company that designs, manufactures, and sells the Invisalign® system of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry, reported financial results for the second quarter of fiscal 2022.

The Board of Directors of Cigna Corporation declared a cash dividend of $1.12 per share of Cigna common stock, payable on September 22, 2022 to shareholders of record as of the close of business on September 7, 2022.

Genomma Lab Internacional, S.A.B. de C.V. (BMV: LAB B) (“Genomma Lab” or “the Company”), today announced its results for the second quarter ended June 30, 2022.

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced today that scientists from the Regeneron Genetics Center® (RGC) have uncovered rare genetic loss-of-function mutations in the CIDEB gene that are associated with substantial protection from liver disease, including serious diseases such as nonalcoholic steatohepatitis (NASH) and cirrhosis.